

● PRINTER RUSH ●
(PTO ASSISTANCE)

Application :	10/015184	Examiner :	McIntosh
From:	NIB	Location:	IDC FMF FDC
		GAU :	
		Date: 8-7-05	
		Tracking #:	010121041
		Week Date:	7-4-05

DOC CODE	DOC DATE	MISCELLANEOUS
<input type="checkbox"/> 1449		<input type="checkbox"/> Continuing Data
<input type="checkbox"/> IDS		<input type="checkbox"/> Foreign Priority
<input type="checkbox"/> CLM		<input type="checkbox"/> Document Legibility
<input type="checkbox"/> IIFW		<input type="checkbox"/> Fees
<input type="checkbox"/> SRFW		<input type="checkbox"/> Other
<input type="checkbox"/> DRW		
<input type="checkbox"/> OATH		
<input type="checkbox"/> 312		
<input checked="" type="checkbox"/> SPEC	11-16-2001	

[RUSH] MESSAGE: Illegible text on pages 282 + 283. Please resolve.
Thank You, NIB

[XRUSH] RESPONSE: New pages 282 + 283 attached.
INITIALS: KAT

NOTE: This form will be included as part of the official USPTO record, with the Response document coded as XRUSH.

650 Town Center Drive, Suite 620
Costa Mesa, CA 92626-1925
Phone: (714) 708-8555
Fax: (714) 708-8565

Birch, Stewart,
Kolasch & Birch, LLP

Please Confirm Receipt Fax

To: Ms. Lacie Hawkins From: Susan Gorman
Fax: 703-746-4658 Pages: including cover sheet 3
Phone: 703-308-9250 Date: 11 August 2005
Your Ref.: 10/015,184 Our Ref.: 1718 - 0194PUS1
Re: _____ CC: _____

Urgent For Review Please Comment Please Reply Please Recycle

This transmission is intended for the sole use of the individual and entity to whom it is addressed, and may contain information that is privileged, confidential and exempt from disclosure under applicable law. You are hereby notified that any dissemination, distribution or duplication of this transmission by someone other than the intended addressee or its designated agent is strictly prohibited. If your receipt of this transmission is in error, please notify this firm immediately by collect call to (714) 708-8555, and send the original transmission to us by return mail at the address above.

• Comments:

Dear Ms. Hawkins,

Please find attached pages 282 & 283
from the 10/015,184 application.

Page 282 begins with ³¹P-NMR ... Example A-4

Page 283 begins with a) 4-Benzylloxycarbonylamin...
many Thanks,

Susan Gorman

³¹P-NMR (CDCl₃+5%CD₃OD)(H₃PO₄ reference): δ 14.9 (s).

Example A-4

4-Amino-1-hydroxybutylidene-1,1-bisphosphonic acid, di (2-(L-valyloxy)-3-methyl-(S)-(+)-butyryloxymethyl) ester.

- a) 4-Benzylloxycarbonylamino-1-hydroxybutylidene-1,1-bisphosphonic acid, di (2-(N-benzylloxycarbonyl-L-valyloxy)-3-methyl-(S)-(+)-butyryloxymethyl) ester.

4-Benzylloxycarbonylamino-1-hydroxybutylidene-1,1-bisphosphonic acid (383 mg, 1 mmole) was esterified by the method described in Example A-3-a to yield 184 mg of title compound. R_f (20%MeOH/CHCl₃) 0.20 (at the center of oval spot from baseline).

¹H-NMR (CDCl₃+ 1%CD₃OD): 7.27 (m, 15H), 5.62 (m, 4H), 5.15-4.72 (m, 8H), 4.32 (m, 2H), 3.08 (m, 2H), 2.16-1.73 (m, 6H), 0.88 (m, 24H). ³¹P-NMR (CDCl₃+1%CD₃OD)(H₃PO₄ reference): δ 15.5 (s).

- b) 4-Amino-1-hydroxybutylidene-1,1-bisphosphonic acid, di (2-(L-valyloxy)-3-methyl-(S)-(+)-butyryloxymethyl) ester.

4-Benzylloxycarbonylamino-1-hydroxybutylidene-1,1-bisphosphonic acid, di (2-(N-benzylloxycarbonyl-L-valyloxy)-3-methyl-(S)-(+)-butyryloxymethyl) ester (184 mg, 0.166 mmol) was hydrogenated over Pd-black (71 mg) by the method of Example A-1-b, to give the title compound as the triacetate as a white solid (95 mg).

³¹P-NMR (CDCl₃+5%CD₃OD)(H₃PO₄ reference): δ 14.6 (s).

Example A-5

4-amino-1-hydroxybutylidene-1,1-bisphosphonic acid, mono (2-methyl-2-(L-valyloxymethyl) propionyloxymethyl) ester.

- a) 4-Benzylloxycarbonylamino-1-hydroxybutylidene-1,1-bisphosphonic acid, tribenzyl mono (2-methyl-2-(N-benzylloxycarbonyl-L-valyloxymethyl) propionyloxymethyl) ester.

To a solution of 4-benzylloxycarbonylamino-1-hydroxybutylidene-1,1-bisphosphonic acid (1.54 g, 4 mmole) in dry N,N-dimethylformamide (24 ml), heated at 50 °C, was added diisopropylethylamine (2.78 ml, 16 mmole), followed by dropwise addition of benzylbromide (1.9 ml, 16 mmole). After stirring under argon for 4 h, the solution was concentrated on rotavapor and treated with ethyl acetate (20 ml). Crystals were filtered off and the filtrate was extracted with brine. The organic phase was filtered through anhydrous sodium sulfate and evaporated. The 4-benzylloxycarbonylamino-1-hydroxybutylidene-1,1-bisphosphonic acid, tribenzylester was isolated by silica gel column chromatography (2-4, 7-10, 15-20% ethanol in dichloromethane). The pure fractions containing the pure triester were pooled together and evaporated. The residue was then dissolved in ethyl acetate and the solution extracted three times with 2M aqueous solution of citric acid. Triester (990 mg); R_f (20%MeOH/ CHCl₃) 0.15 (at the center of oval spot from baseline);

³¹P-NMR (CDCl₃) (H₃PO₄ reference): δ 20.4(d), 13.3 (d); ¹H-NMR (CDCl₃): 7.35-7.10 (m, 20H), 5.20-4.91 (m, 8H), 4.60 (br, 1H), 3.00 (m, 2H), 2.12-1.75 (m, 4H).

- b) Dried tribenzyl ester (395 mg) was dissolved in dry N,N-dimethylformamide (3 ml), followed by addition of diisopropylethylamine (99 ml) and a solution of iodomethyl 2-methyl-2-(N-benzylloxycarbonyl-L-valyloxymethyl) propionate (737 mg) in N,N-dimethylformamide (1 ml). After stirring under argon for 4 h at 30 °C, the solution was concentrated to dryness on rotavapor and treated with ethyl acetate (10 ml). Crystals were filtered off and the filtrate was extracted with brine containing a small amount of sodium thiosulfate. The organic phase was filtered through anhydrous sodium sulfate and evaporated. The title compound (84 mg) was isolated by silica gel column chromatography (1, 2, 3% ethanol in dichloromethane). R_f (2%MeOH/ CHCl₃) 0.60;